Gab2 regulates the migratory behaviors and E-cadherin expression via activation of the PI3K pathway in ovarian cancer cells

Oncogene

Volumn 31, Issue 20, 2012, Pages 2512-2520

  Wang, Y ^a   Sheng, Q ^a   Spillman, M A ^b   Behbakht, K ^b   Gu, H ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

E cadherin; EMT; Gab2; ovarian cancer; PI3K; Zeb1

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ADAPTOR PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MUTANT PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PICTRELISIB; PROTEIN GAB2; PROTEIN TYROSINE PHOSPHATASE SHP 2; RAPAMYCIN; SCAFFOLD PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ZEB 1; UNCLASSIFIED DRUG; UVOMORULIN;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS; OVARY CANCER; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CADHERINS; CELL LINE, TUMOR; CELL MOVEMENT; ENZYME INHIBITORS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; INDAZOLES; MUTANT PROTEINS; OVARIAN NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; SIGNAL TRANSDUCTION; SULFONAMIDES; TRANSCRIPTION FACTORS;

EID: 84861409108     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.435     Document Type: Article

References (40)

1. Abreu MT, Hughes WE, Mele K, Lyons RJ, Rickwood D, Browne BC et al. (2011). Gab2 regulates cytoskeletal organization and migration of mammary epithelial cells by modulating RhoA activation. Mol Biol Cell 22: 105-116.
2. Agarwal R, Carey M, Hennessy B, Mills GB. (2010). PI3K pathwaydirected therapeutic strategies in cancer. Curr Opin Investig Drugs 11: 615-628.
3. Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S et al. (2004). The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 3: 772-775. (Pubitemid 41351083)
4. Bast Jr RC, Hennessy B, Mills GB. (2009). The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 9: 415-428.
5. Battini JL, Rasko JE, Miller AD. (1999). A human cell-surface receptor for xenotropic and polytropic murine leukemia viruses: possible role in G protein-coupled signal transduction. Proc Natl Acad Sci USA 96: 1385-1390. (Pubitemid 29098460)
6. Bennett HL, Brummer T, Jeanes A, Yap AS, Daly RJ. (2008). Gab2 and Src co-operate in human mammary epithelial cells to promote growth factor independence and disruption of acinar morphogenesis. Oncogene 27: 2693-2704. (Pubitemid 351581464)
7. Bentires-Alj M, Gil SG, Chan R, Wang ZC, Wang Y, Imanaka N et al. (2006). A role for the scaffolding adapter GAB2 in breast cancer. Nat Med 12: 114-121. (Pubitemid 43050085)
8. Bocanegra M, Bergamaschi A, Kim YH, Miller MA, Rajput AB, Kao J et al. (2010). Focal amplification and oncogene dependency of GAB2 in breast cancer. Oncogene 29: 774-779.
9. Brown LA, Kalloger SE, Miller MA, Shih Ie M, McKinney SE, Santos JL et al. (2008). Amplification of 11q13 in ovarian carcinoma. Genes Chromosomes Cancer 47: 481-489. (Pubitemid 351657183)
10. Brummelkamp TR, Bernards R, Agami R. (2002). Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2: 243-247. (Pubitemid 41043979)
11. Brummer T, Schramek D, Hayes VM, Bennett HL, Caldon CE, Musgrove EA et al. (2006). Increased proliferation and altered growth factor dependence of human mammary epithelial cells overexpressing the Gab2 docking protein. J Biol Chem 281: 626-637. (Pubitemid 43671226)
12. Cheng JC, Auersperg N, Leung PC. (2011). Inhibition of p53 induces invasion of serous borderline ovarian tumor cells by accentuating PI3K/Akt-mediated suppression of E-cadherin. Oncogene 30: 1020-1031.
13. Daly RJ, Gu H, Parmar J, Malaney S, Lyons RJ, Kairouz R et al. (2002). The docking protein Gab2 is overexpressed and estrogen regulated in human breast cancer. Oncogene 21: 5175-5181.
14. Engelman JA. (2009). Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9: 550-562.
15. Feeley KM, Wells M. (2001). Precursor lesions of ovarian epithelial malignancy. Histopathology 38: 87-95. (Pubitemid 32193623)
16. Fleuren ED, O'Toole S, Millar EK, McNeil C, Lopez-Knowles E, Boulghourjian A et al. (2010). Overexpression of the oncogenic signal transducer Gab2 occurs early in breast cancer development. Int J Cancer 127: 1486-1492.
17. Gu H, Neel BG. (2003). The 'Gab' in signal transduction. Trends Cell Biol 13: 122-130. (Pubitemid 36293784)
18. Gu H, Pratt JC, Burakoff SJ, Neel BG. (1998). Cloning of p97/Gab2, the major SHP-2 binding protein in hematopoietic cells, reveals a novel pathway for cytokine-induced gene activation. Mol Cell 2: 729-740. (Pubitemid 128378981)
19. Horst B, Gruvberger-Saal SK, Hopkins BD, Bordone L, Yang Y, Chernoff KA et al. (2009). Gab2-mediated signaling promotes melanoma metastasis. Am J Pathol 174: 1524-1533.
20. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E et al. (2004).Cancer statistics, 2004. CA Cancer J Clin 54: 8-29.
21. Karst AM, Levanon K, Drapkin R. (2011). Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. Proc Natl Acad Sci USA 108: 7547-7552.
22. Ke Y, Wu D, Princen F, Nguyen T, Pang Y, Lesperance J et al. (2007). Role of Gab2 in mammary tumorigenesis and metastasis. Oncogene 26: 4951-4960. (Pubitemid 47172654)
23. Kolasa IK, Rembiszewska A, Felisiak A, Ziolkowska-Seta I, Murawska M, Moes J et al. (2009). PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients. Cancer Biol Ther 8: 21-26.
24. Kong D, Dan S, Yamazaki K, Yamori T. (2010). Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39. Eur J Cancer 46: 1111-1121.
25. Kosary C. (2007). Chapter 16: Cancers of the Ovary in SEER Survival Monograph: Cancer Survival Among Adults: US SEER Program, 1988-2001, Patient and Tumor Characteristics. NIH Pub. No. 07-6215 NCI: Bethesda, MD, USA, pp 133-144.
26. Kurman RJ, Shih Ie M. (2010). The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 34: 433-443.
27. Larue L, Bellacosa A. (2005). Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 30 kinase/AKT pathways. Oncogene 24: 7443-7454. (Pubitemid 41637984)
28. Levanon K, Crum C, Drapkin R. (2008). New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol 26: 5284-5293.
29. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI et al. (1997). PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943-1947. (Pubitemid 27148818)
30. Luo J, Manning BD, Cantley LC. (2003). Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 4: 257-262. (Pubitemid 37329790)
31. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S et al. (2004). High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554. (Pubitemid 38541907)
32. Sheng Q, Liu X, Fleming E, Yuan K, Piao H, Chen J et al. (2010). An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell 17: 298-310.
33. Shih Ie M, Kurman RJ. (2004). Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 164: 1511-1518. (Pubitemid 38529752)
34. Shih Ie M, Sheu JJ, Santillan A, Nakayama K, Yen MJ, Bristow RE et al. (2005). Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. Proc Natl Acad Sci USA 102: 14004-14009. (Pubitemid 41377693)
35. Spandidos A, Wang X, Wang H, Seed B. (2010). PrimerBank: a resource of human and mouse PCR primer pairs for gene expression detection and quantification. Nucleic Acids Res 38: D792-D799.
36. Tan DS, Agarwal R, Kaye SB. (2006). Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol 7: 925-934. (Pubitemid 44615952)
37. Tan DS, Ang JE, Kaye SB. (2008). Ovarian cancer: can we reverse drug resistance? Adv Exp Med Biol 622: 153-167.
38. Wells A, Yates C, Shepard CR. (2008). E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas. Clin Exp Metastasis 25: 621-628.
39. Wohrle FU, Daly RJ, Brummer T. (2009). Function, regulation and pathological roles of the Gab/DOS docking proteins. Cell Commun Signal 7: 22.
40. Yang J, Weinberg RA. (2008). Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 14: 818-829. (Pubitemid 351757205)